OBJECTIVE: The mouse serves as an important model for insulin-like (IGF)-related research. However, lack of homologous mouse assays has prevented studies of the normal ontology of the murine IGF system. Therefore, we developed and validated immunoaassays for murine IGF-I, IGFBP-3 and ALS and studied levels of these analytes in mice. METHODS: Using commercially available reagents, we developed and validated specific enzyme-linked immunosorbent assays (ELISAs) for murine IGF-I, IGFBP-3, and ALS. Levels of these analytes were measured in sera from CD-1 mice, male and female, sampled at 1, 2, 4, 8, 20 and 32 weeks of age. In addition, sera from pregnant and postpartum CD-1 mice were also studied. RESULTS: Validation of specific ELISAs for murine IGF-I, IGFBP-3 and ALS are described; all 3 assays were highly sensitive, precise and accurate. As measured by our homologous ELISA, IGF-I levels (ng/mL, mean+/-SD) in male mice were relatively low at 1 week (53+/-8), rising sharply to peak at 8 weeks of age (636+/-48), and gradually declining thereafter, reaching 395+/-64 at 32 weeks. IGF-I levels in non-pregnant female mice peaked at 4 weeks of age (548+/-77) declined at 8 weeks (417+/-61), then recovered to plateau at 539+/-78 and 535+/-88 at 20 and 32 weeks, respectively. In male mice, trends in IGFBP-3 were similar to the patterns of IGF-I. However, in non-pregnant female mice, the IGFBP-3 levels declined relatively slowly after peaking at 4-weeks of age, unlike IGF-I levels during this period. ALS levels followed the same pattern as IGF-I in both sexes. IGF-I to IGFBP-3 molar ratios (percent) were similar between sexes, rising continuously with age: approximately 30% at 1 week, 80% at 4 weeks, 135% at 32 weeks. IGF-I was reduced in 8 week old mice in mid-pregnancy (354+/-75 vs 417+/-61 in non-pregnant 8 week females), reaching a nadir in late-term (146+/-40), and only partially recovering in the postpartum period (239+/-23). IGFBP-3 was also lower in late-pregnancy (1245+/-100 vs 1925+/-439) and remained depressed postpartum. In contrast to IGF-I and IGFBP-3, ALS increased more than threefold in mid-pregnancy (12180+/-1641 vs 3741+/-910), followed by a 4-fold decrease in late-pregnancy (2964+/-489), recovering postpartum (6104+/-1178). CONCLUSIONS: We report the first ontological studies of IGF-I, IGFBP-3 and ALS in mice using newly-characterized sensitive, homologous immunoassays. Our results indicate that mice have a generally similar pattern in IGF-related axis components, with low levels early in life, increasing to peak during sexual maturation and declining thereafter. Significant gender differences in non-pregnant levels and dramatic changes during pregnancy were also found. Knowledge of the normal developmental changes in the murine IGF system and accurate tools for investigations of this system are a necessary foundation for research in this field.
OBJECTIVE: The mouse serves as an important model for insulin-like (IGF)-related research. However, lack of homologous mouse assays has prevented studies of the normal ontology of the murine IGF system. Therefore, we developed and validated immunoaassays for murineIGF-I, IGFBP-3 and ALS and studied levels of these analytes in mice. METHODS: Using commercially available reagents, we developed and validated specific enzyme-linked immunosorbent assays (ELISAs) for murineIGF-I, IGFBP-3, and ALS. Levels of these analytes were measured in sera from CD-1 mice, male and female, sampled at 1, 2, 4, 8, 20 and 32 weeks of age. In addition, sera from pregnant and postpartum CD-1 mice were also studied. RESULTS: Validation of specific ELISAs for murineIGF-I, IGFBP-3 and ALS are described; all 3 assays were highly sensitive, precise and accurate. As measured by our homologous ELISA, IGF-I levels (ng/mL, mean+/-SD) in male mice were relatively low at 1 week (53+/-8), rising sharply to peak at 8 weeks of age (636+/-48), and gradually declining thereafter, reaching 395+/-64 at 32 weeks. IGF-I levels in non-pregnant female mice peaked at 4 weeks of age (548+/-77) declined at 8 weeks (417+/-61), then recovered to plateau at 539+/-78 and 535+/-88 at 20 and 32 weeks, respectively. In male mice, trends in IGFBP-3 were similar to the patterns of IGF-I. However, in non-pregnant female mice, the IGFBP-3 levels declined relatively slowly after peaking at 4-weeks of age, unlike IGF-I levels during this period. ALS levels followed the same pattern as IGF-I in both sexes. IGF-I to IGFBP-3 molar ratios (percent) were similar between sexes, rising continuously with age: approximately 30% at 1 week, 80% at 4 weeks, 135% at 32 weeks. IGF-I was reduced in 8 week old mice in mid-pregnancy (354+/-75 vs 417+/-61 in non-pregnant 8 week females), reaching a nadir in late-term (146+/-40), and only partially recovering in the postpartum period (239+/-23). IGFBP-3 was also lower in late-pregnancy (1245+/-100 vs 1925+/-439) and remained depressed postpartum. In contrast to IGF-I and IGFBP-3, ALS increased more than threefold in mid-pregnancy (12180+/-1641 vs 3741+/-910), followed by a 4-fold decrease in late-pregnancy (2964+/-489), recovering postpartum (6104+/-1178). CONCLUSIONS: We report the first ontological studies of IGF-I, IGFBP-3 and ALS in mice using newly-characterized sensitive, homologous immunoassays. Our results indicate that mice have a generally similar pattern in IGF-related axis components, with low levels early in life, increasing to peak during sexual maturation and declining thereafter. Significant gender differences in non-pregnant levels and dramatic changes during pregnancy were also found. Knowledge of the normal developmental changes in the murine IGF system and accurate tools for investigations of this system are a necessary foundation for research in this field.
Authors: T Modric; J V Silha; Z Shi; Y Gui; A Suwanichkul; S K Durham; D R Powell; L J Murphy Journal: Endocrinology Date: 2001-05 Impact factor: 4.736
Authors: R C Baxter; M Svejkar; M J Khosravi; G L Bennett; K V Hardman; A Senese; J Mistry; P E Walton; V Quarmby Journal: J Endocrinol Date: 2000-05 Impact factor: 4.286
Authors: S Stadler; Z Wu; R A Dressendörfer; K M Morrison; A Khare; P D Lee; C J Strasburger Journal: J Immunol Methods Date: 2001-06-01 Impact factor: 2.303
Authors: A Juul; P Dalgaard; W F Blum; P Bang; K Hall; K F Michaelsen; J Müller; N E Skakkebaek Journal: J Clin Endocrinol Metab Date: 1995-08 Impact factor: 5.958
Authors: B Heidler; N Parvizi; H Sauerwein; R M Bruckmaier; U Heintges; J E Aurich; C Aurich Journal: Domest Anim Endocrinol Date: 2003-07 Impact factor: 2.290
Authors: Francisco Javier Cisneros; Ralph Wilson; Gregory Travlos; Lucy M Anderson; Stacy Branch Journal: Life Sci Date: 2003-05-09 Impact factor: 5.037
Authors: Ramdev Konijeti; Susanne Henning; Aune Moro; Ahmed Sheikh; David Elashoff; Ari Shapiro; Melvin Ku; Jonathan W Said; David Heber; Pinchas Cohen; William J Aronson Journal: Prostate Date: 2010-10-01 Impact factor: 4.104
Authors: YanHe Lue; Ronald Swerdloff; Junxiang Wan; Jialin Xiao; Samuel French; Vince Atienza; Victor Canela; Kevin W Bruhn; Brian Stone; Yue Jia; Pinchas Cohen; Christina Wang Journal: Endocrinology Date: 2015-09-18 Impact factor: 4.736
Authors: Makoto Anzo; Laura J Cobb; David L Hwang; Hemal Mehta; Jonathan W Said; Shoshana Yakar; Derek LeRoith; Pinchas Cohen Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: James P Dean; Cynthia C Sprenger; Junxiang Wan; Kathleen Haugk; William J Ellis; Daniel W Lin; John M Corman; Bruce L Dalkin; Elahe Mostaghel; Peter S Nelson; Pinchas Cohen; Bruce Montgomery; Stephen R Plymate Journal: J Clin Endocrinol Metab Date: 2013-03-26 Impact factor: 5.958